[G17-11] Obinutuzumab (non-pretreated advanced follicular lymphoma) - Assessment according to §35a (1), Sentence 11, Social Code Book V
Last updated 15.01.2018
Project no.:
G17-11
Commission:
Commission awarded on 11.10.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
In accordance with § 35a (para. 1, sentence 11) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Obinutuzumab report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.
| Project no. | Title | Status |
|---|---|---|
| G16-07 | Obinutuzumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V | Commission completed |
| G14-08 | Obinituzumab - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A21-64 | Obinutuzumab (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-65 | Obinutuzumab (follicular lymphoma, after rituximab) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-66 | Obinutuzumab (follicular lymphoma, first line) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2018-04-05 A G-BA decision was published.